Novo Fails to Shrug Off Investor Concern at Q2 Update
15 Articles
15 Articles
Novo Nordisk ended with a decline of 4.3 percent on the Copenhagen stock exchange.
The Danish company speaks of a "pleasant use" of its Wegovy pill in the USA. Now the drug is also to conquer the European market. But competitor Eli Lilly is close to the heels.
Novo Nordisk makes more money than expected. Yet the share price falls – to the surprise of analysts.
The syringe for weight loss has been on the market for a long time, now Novo Nordisk wants to bring the medicine to Germany in pill form as well. Meanwhile, the Group's share is under pressure.
The Novo Nordisk share fell on the stock exchange in Denmark on Wednesday. The share fell to the bottom of the C25 index in the morning and has since been down between 2 and 4 percent. But by noon on Wednesday, the share...
Coverage Details
Bias Distribution
- 43% of the sources lean Left, 43% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
